Targeted approaches for the treatment of thrombocytopenia

Oncologist

Volumn 6, Issue SUPPL. 5, 2001, Pages 15-23

  Demetri, G D ^a  

^a DANA FARBER CANCER INSTITUTE   (United States)

Author keywords

C Mpl; Platelet transfusion; Thrombocytopenia; Thrombopoiesis; Thrombopoietin

Indexed keywords

CELL SURFACE RECEPTOR; GRANULOCYTE COLONY STIMULATING FACTOR; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; RECOMBINANT ERYTHROPOIETIN; RECOMBINANT INTERLEUKIN 11; THROMBOPOIETIN RECEPTOR;

ANEMIA; CARDIOVASCULAR DISEASE; CONFERENCE PAPER; DRUG EFFICACY; DRUG MECHANISM; DRUG RECEPTOR BINDING; EDEMA; ERYTHROPOIESIS; FATIGUE; GRANULOPOIESIS; HUMAN; INFECTION; MYALGIA; NEUTROPENIA; PRIORITY JOURNAL; THROMBOCYTE COUNT; THROMBOCYTE TRANSFUSION; THROMBOCYTOPENIA;

EID: 0035172482     PISSN: 10837159     EISSN: None     Source Type: Journal    
DOI: 10.1634/theoncologist.6-suppl_5-15     Document Type: Conference Paper

References (57)

1. The role of platelet growth factors in cancer therapy
2. Pharmacologic treatment options in patients with thrombocytopenia
3. Molecular cloning and characterization of MPL, the human homolog of the v-mpl oncogene: Identification of a member of the hematopoietic growth factor receptor superfamily
4. cMpl ligand is a humoral regulator of megakaryocytopoiesis
5. Current issues with platelet transfusion in patients with cancer
6. Human platelets loaded with trehalose survive freeze-drying
7. Bovine spongiform encephalopathy and variant Creutzfeldt-Jakob disease: Background, evolution, and current concerns
8. Supportive care in hematologic malignancies: Hematopoietic growth factors, infections, transfusion therapy
9. What are the true costs of platelet transfusions? A prospective time motion study of resource utilization associated with platelet transfusions at UCLA medical center
10. Platelet transfusions: Utilization and associated costs in a tertiary care hospital
11. Economic consequences of alterations in platelet transfusion dose: Analysis of a prospective, randomized, double-blind trial
12. Platelet transfusion for patients with cancer: Clinical practice guidelines of the American Society of Clinical Oncology
13. The use of leukocyte-reduced blood components
14. Pathophysiology of febrile nonhemolytic transfusion reactions
15. Platelet washing to prevent recurrent febrile reactions to leucocyte-reduced transfusions
16. The utility of < or = 3-day-old whole-blood platelets in reducing the incidence of febrile nonhemolytic transfusion reactions
17. Single-donor platelets reduce the risk of septic platelet transfusion reactions
18. Thrombopoietin stimulation of hematopoietic stem/progenitor cells
19. Effect of a single dose of pegylated human recombinant megakaryocyte growth and development factor (PEG-rHuMGDF) on platelet counts: Implications for platelet apheresis
20. Megakaryocyte potentiating activity of IL-1, IL-6 and GM-CSF as evaluated by their action on in vitro human megakaryocytic colonies
21. A combination of megakaryocyte growth and development factor and interleukin-1 is sufficient to culture large numbers of megakaryocytic progenitors and megakaryocytes for transfusion purposes
22. Interleukin-1: Biological effects in human hematopoiesis
23. The effects of treatment with interleukin-1α on platelet recovery after high-dose carboplatin
24. Effects of interleukin-1α on carboplatin-induced thrombocytopenia in patients with recurrent ovarian cancer
25. Interaction of monocytes and T cells in the regulation of normal human megakaryocytopoiesis in vitro: Role of IL-1 and IL-2
26. Megakaryocytopoiesis in vitro: From the stem cells' perspective
27. Interleukin 3 in the treatment of chemotherapy induced thrombocytopenia
28. The effect of interleukin 3 upon lgE-dependent and IgE-independent basophil degranulation and leukotriene generation
29. Acceleration of hematopoietic reconstitution with a synthetic cytokine (SC-55494) after radiation-induced bone marrow aplasia
30. A phase I trial of recombinant human interleukin-6 in patients with myelodysplastic syndromes and thrombocytopenia
31. Phase I multicenter trial of interleukin 6 therapy after autologous bone marrow transplantation in advanced breast cancer
32. Thrombopoietic effects and toxicity of interleukin-6 in patients with ovarian cancer before and after chemotherapy: A multicentric placebo-controlled, randomized phase Ib study
33. Recombinant human interleukin-6 induces a rapid and reversible anemia in cancer patients
34. Measurements of in vivo megakaryocytopoiesis: Studies in nonhuman primates and patients
35. Effect of low-dose granulocyte-macrophage colony-stimulating factor (LD-GM-CSF) on platelet transfusion-dependent thrombocytopenia
36. Randomized, double-blind, placebo-controlled trial to evaluate the hematopoietic growth h factor P1XY321 after moderate-dose fluorouracil, doxorubicin, and cyclophosphamide in stage II and III breast cancer
37. Effect of interleukin II on normal and pathological thrombopoiesis
38. Effects of recombinant human interleukin-11 (Neumega rHuIL-11 growth factor) on megakaryocytopoiesis in human bone marrow
39. A phase I trial of recombinant human interleukin-11 (Neumega rHuIL-11 (Neumeea rHuIL-11 growth factor) in women with breast cancer receiving chemotherapy
40. Randomized placebocontrolled study of recombinant human interleukin-11 to prevent chemotherapy-induced thrombocytopenia in patients with breast cancer receiving dose-intensive cyclophosphamide and doxorubicin
41. A randomized placebo-controlled trial of recombinant human interleukin-II in cancer patients with severe thrombocytopenia due to chemotherapy
42. A randomized trial of recombinant human interleukin-11 following autologous bone marrow transplantation with peripheral blood progenitor cell support in patients with breast cancer
43. Demonstration and some properties of human thrombopoietin in thrombocythaemic sera
44. A clonogenic common myeloid progenitor that gives rise to all myeloid lineages
45. Hematopoietic deficiencies in c-mpl and TPO knockout mice
46. Hematopoietic stem cell deficiencies in mice lacking c-Mpl, the receptor for thrombopoietin
47. Stimulation of megakaryocytopoiesis and thrombopoiesis by the c-Mpl ligand
48. Cloning and expression of murine thrombopoietin cDNA and stimulation of platelet production in vivo
49. Identification and cloning of a megakaryocyte growth and development factor that is a ligand for the cytokine receptor Mpl
50. Molecular cloning and chromosomal localization of the human thrombopoietin gene
51. Megakaryocyte growth and development factor (MGDF): An Mpl ligand and cytokine that regulates thrombopoiesis
52. Stimulation of megakaryocyte and platelet production by a single dose of recombinant human thrombopoietin in patients with cancer
53. Recombinant human thrombopoietin attenuates carboplatininduced severe thrombocytopenia and the need for platelet transfusions in patients with gynecologic cancer
54. Immunogenicity of thrombopoietin mimetic peptide GW395058 in BALB/c mice and New Zealand white rabbits: Evaluation of the potential for thrombopoietin neutralizing antibody production in man
55. The pharmacokinetics and pharmacodynamics of GW395058, a peptide agonist of the thrombopoietin receptor, in the dog, a large-animal model of chemotherapy-induced thrombocytopenia
56. Megakaryocyte ex vivo expansion potential of three hematopoietic sources in serum and serum-free medium